The influence of olanzapine on immune cells in patients with schizophrenia

In vitro and preclinical studies show that biochemical and behavioral effects of olanzapine are quite similar to those of clozapine. In recent years, some cases of reported agranulocytosis due to olanzapine have been published. However, none of these studies compared the hematological and immune par...

Full description

Saved in:
Bibliographic Details
Published in:Progress in neuro-psychopharmacology & biological psychiatry 2003-05, Vol.27 (3), p.483-485
Main Authors: Bilici, Mustafa, Tekelioğlu, Yavuz, Efendioğlu, Saniye, Ovalı, Ercüment, Ülgen, Metin
Format: Article
Language:English
Subjects:
Adolescent
Adult
Benzodiazepines
Biological and medical sciences
Clozapine
Drug toxicity and drugs side effects treatment
Female
Humans
Immune impairment
Immunity, Cellular - drug effects
Immunity, Cellular - immunology
Lymphocytes - drug effects
Lymphocytes - immunology
Male
Medical sciences
Middle Aged
Olanzapine
Patients - statistics & numerical data
Pharmacology. Drug treatments
Pirenzepine - analogs & derivatives
Pirenzepine - pharmacology
Pirenzepine - therapeutic use
Schizophrenia
Schizophrenia - drug therapy
Schizophrenia - immunology
Schizophrenia - metabolism
Statistics, Nonparametric
Toxicity: blood
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:In vitro and preclinical studies show that biochemical and behavioral effects of olanzapine are quite similar to those of clozapine. In recent years, some cases of reported agranulocytosis due to olanzapine have been published. However, none of these studies compared the hematological and immune parameters before and after treatment. The present study is aimed at investigating the influence of olanzapine on the immune cell parameters by comparing these before and in the third month of olanzapine treatment in patients of schizophrenia. Twenty patients who were diagnosed as schizophrenic depending on the DSM-IV diagnostic criteria were included in the study. The immune parameters of patients were compared by measuring them before the treatment and 3 months after treatment. Immune parameters were analyzed by using flow-cytometry equipment labeled Coulter Epics Elite ESP. The positivity of cell-surface antibody was evaluated as percentage. The rates of CD8 in the third month of the treatment were considerably increased relative to pretreatment. Furthermore, rates of CD4/CD8 were significantly decreased in the third month of the treatment relative to before treatment. These findings suggest that immune impairment may occur during olanzapine treatment in patients with schizophrenia.
ISSN:0278-5846
1878-4216
DOI:10.1016/S0278-5846(03)00036-8